Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

NCT01270906 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Cancer
Tumors

Interventions

DRUG: CHIR-258 (TKI258)

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]